Key Points
- Director Blake Borgeson sold 40,000 Recursion Pharmaceuticals shares for $155,200 at an average price of $3.88, under a pre-arranged Rule 10b5-1 plan. He retained 6,068,287 shares after the sale.
- Recursion reported quarterly EPS of -$0.22, matching estimates, while revenue of $18.55 million exceeded the $14.81 million consensus estimate.
- Analysts’ consensus rating is Hold, with an average price target of $8.18; shares opened at $3.88 and were reported up 5.4%.
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Get Free Report) Director Blake Borgeson sold 40,000 shares of the firm's stock in a transaction that occurred on Tuesday, November 3rd. The shares were sold at an average price of $3.88, for a total value of $155,200.00. Following the completion of the transaction, the director directly owned 6,068,287 shares of the company's stock, valued at $23,544,953.56. The trade was a 0.65% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Blake Borgeson also recently made the following trade(s):
- On Tuesday, October 6th, Blake Borgeson sold 50,000 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $4.84, for a total value of $242,000.00.
- On Tuesday, September 1st, Blake Borgeson sold 30,000 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $3.34, for a total value of $100,200.00.
Recursion Pharmaceuticals Stock Up 5.4%
Shares of RXRX stock opened at $3.88 on Thursday. Recursion Pharmaceuticals, Inc. has a fifty-two week low of $2.77 and a fifty-two week high of $5.24. The stock has a market cap of $2.08 billion, a P/E ratio of -4.31 and a beta of 1.15. The business has a fifty day simple moving average of $3.77 and a 200-day simple moving average of $3.53.
Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last released its quarterly earnings results on Monday, November 2nd. The company reported ($0.22) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.22). Recursion Pharmaceuticals had a negative return on equity of 47.85% and a negative net margin of 697.15%. The business had revenue of $18.55 million during the quarter, compared to the consensus estimate of $14.81 million. During the same quarter in the previous year, the company posted ($0.36) EPS. On average, sell-side analysts anticipate that Recursion Pharmaceuticals, Inc. will post -0.93 earnings per share for the current year.
Analyst Upgrades and Downgrades
A number of brokerages have issued reports on RXRX. Wall Street Zen upgraded shares of Recursion Pharmaceuticals from a "strong sell" rating to a "sell" rating in a research report on Saturday, October 17th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Recursion Pharmaceuticals in a report on Thursday, October 15th. Needham & Company LLC reiterated a "buy" rating and issued a $8.00 price target on shares of Recursion Pharmaceuticals in a research report on Monday, October 19th. Finally, Morgan Stanley set a $5.90 price objective on shares of Recursion Pharmaceuticals in a research note on Friday, October 16th. Two investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, Recursion Pharmaceuticals currently has a consensus rating of "Hold" and a consensus price target of $8.18.
Get Our Latest Report on Recursion Pharmaceuticals
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Ascent Wealth Partners LLC grew its position in Recursion Pharmaceuticals by 11.8% in the first quarter. Ascent Wealth Partners LLC now owns 28,081 shares of the company's stock valued at $86,000 after acquiring an additional 2,974 shares in the last quarter. Cherry Creek Investment Advisors Inc. raised its stake in shares of Recursion Pharmaceuticals by 5.8% during the first quarter. Cherry Creek Investment Advisors Inc. now owns 70,536 shares of the company's stock valued at $217,000 after purchasing an additional 3,859 shares during the period. PNC Financial Services Group Inc. lifted its position in shares of Recursion Pharmaceuticals by 33.2% during the first quarter. PNC Financial Services Group Inc. now owns 16,832 shares of the company's stock worth $52,000 after purchasing an additional 4,199 shares in the last quarter. Sequoia Financial Advisors LLC lifted its position in shares of Recursion Pharmaceuticals by 51.5% during the first quarter. Sequoia Financial Advisors LLC now owns 15,162 shares of the company's stock worth $47,000 after purchasing an additional 5,156 shares in the last quarter. Finally, Axxcess Wealth Management LLC lifted its position in shares of Recursion Pharmaceuticals by 16.6% during the first quarter. Axxcess Wealth Management LLC now owns 37,516 shares of the company's stock worth $115,000 after purchasing an additional 5,338 shares in the last quarter. 89.06% of the stock is currently owned by hedge funds and other institutional investors.
Recursion Pharmaceuticals Company Profile
(
Get Free Report)
Recursion Pharmaceuticals, Inc is a biotechnology company that uses advanced computing, artificial intelligence and automated biology to discover and develop new medicines. The company's platform, known as the Recursion Operating System, combines large-scale biological experimentation with machine learning and data analysis to identify potential drug candidates and characterize how diseases respond to treatments.
Recursion applies its technology to a range of therapeutic areas, including oncology, rare diseases, neuroscience and infectious diseases.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
